use of adult stem cells and induced pluripotent stem (iPS) cells. However, it hasn’t all been smooth sailing. Although after protracted forethought, the US Food and Drug Administration (FDA) gave the green light for the Californian biotech Geron to begin the very first human clinical trial of a human embryonic stem cell-derived ther

em and come up with a drug to fix it. But because the United States Food and Drug Administration already has a library of approved compounds that